Quantum-Si Incorporated

Ladies and gentlemen, thank you for standing by and welcome to the Quantum SI first quarter 2022 earnings call. At this time, all participants are on listen mode only. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star one on your telephone. If you require any further assistance, please press star zero. Please be advised, today's conference is being recorded. I would now like to turn the conference over to Juan Avendano, Head of Investor Relations with Quantum SI. Juan, please go ahead.

Good evening, everyone. Thank you for joining us. Today, after market close, Quantum SI released financial results for the first quarter ending March 31st, 2022. A copy of the press release is available on the company's website. Joining me today are Dr. Jonathan Rothberg, Interim Chief Executive Officer, Patrick Schneider, our newly appointed President and Chief Operating Officer, and Claudia Creighton, Chief Financial Officer. Before we begin, I'd like to remind you that management will be making certain forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding this risk and uncertainties appears in the section entitled forward-looking statements of our press release. For a more complete list and description of risk factors, please see the company's findings made with the Securities and Exchange Commission. This conference call contains time-sensitive information that is accurate only as of the live broadcast today, May 9, 2022. Except, as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with U.S. generally accepted accounting principles or GAAP, including adjusted EBITDA. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release. With that, I will turn the call over to Dr. Jonathan Rothbard.

Thank you, Juan. Good afternoon, everyone. Thank you for joining us. In today's call, we will provide a business update and present our first quarter financial performance and outlook for 2022. We will then open the lines for questions. QuantumSI's mission is to transform life science research and proteomics by becoming the first company to launch next generation protein sequencing. We believe that digital, massively parallel, single molecule protein sequencing will revolutionize life science research and healthcare in a similar manner to how next generation DNA sequencing transformed these industries when my team first brought it to market over a decade ago. Our search for a full-time CEO is ongoing. We have met with several high-caliber candidates and have found this process to be valuable in focusing our criteria for this critical hire. As our search continues, we are looking for an individual who has a deep understanding of technology, a proven track record launching complex life science tools, and the velocity, tenacity, and charisma to make QuantumSI a commercial and financial success. As interim CEO, I have been motivated by QuantumSI's team's commitment to our mission. I am now even more confident that we have the right people, technical capabilities, and resources to not only pioneer but also own the fork in history we create with next-generation protein sequencing. While I have loved leading the day-to-day operations of QuantumSI, and have been able to truly appreciate and help advance our technology. I am very excited to announce I have a new partner to raise the probability of our success. I would now like to introduce Patrick Snyder, our new president and chief operating officer. He brings two decades of life science senior leadership experience to Quantum SI. and we are excited to have Patrick on board to enhance our leadership team and allow me to identify strategic opportunities and evangelize next-generation protein sequencing technologies by demonstrating the potential in high-profile projects.